Provaidya LLC, is a biopharmaceutical startup company focused on developing innovative therapies for neurodegenerative diseases. It was founded in 2013 to promote translation of rationally designed novel agents developed as therapeutics for Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases in academic settings. It has won the STTR Award for "Development of peptide inhibitors for neuroinflammation and neurodegeneration. 

Our Mission

Our goal at Provaidya is to cure the spectrum of  neurodegenerative diseases. In this process, Provaidya has taken first steps with evaluating novel mechanism based peptide inhibitors in models of Alzheimer's disease and Multiple Sclerosis.

An estimated 5.4 million Americans of all ages have Alzheimer’s disease in 2016. The number is predicted to increase rapidly to an estimated 13.8 billion barring efficient drug discovery and development to prevent and cure the disease.
— The Alzheimer's Association

Provaidya TEAM

  • Mythily Srinivasan: Chief Executive Officer

Dr. Mythily Srinivasan founded Provaidya LLC in 2013 as a spin-up in collaboration with the Indiana University Research and Technology Corporation. The goal is licensing novel therapeutic peptides developed within her  laboratory as drug candidates for neurodegenerative diseases. She has over 14 years of experience working on rational design and translational applications of drug like immunomodulatory peptide agents. Her research explore potential targets in critical protein: protein interactions intricately associated with abnormal cellular responses, keeping the druggability of the target in focus. Two immunomodulatory peptide agents developed by Dr. Srinivasan have been issued United States patents. Beginning her professional career in dentistry, she received PhD from the Ohio State University with a multidisciplinary training that included peptide chemistry and immunology.  

  • Debomoy K. Lahiri: Director and Chief Scientific Advisor

Dr. Debomoy K Lahiri is Professor of Psychiatry and a senior investigator in Stark Neuroscience Research Center at the Indiana University School of Medicine. He is on the scientific advisory board of many pharmaceutical companies involved in neuroscience drug discovery including QR Pharma, Yuma Therapeutics, Entia Biosciences. He is a member of the International advisory board of the Drug Discovery and Therapy World Congress. He is one of the co-inventors in the QR Pharma patent involving AIT-082, memantine and pending on acamprosate. Dr. Lahiri is the current Editor in Chief of Current Alzheimer Research journal. Dr. Lahiri has received multiple NIH grants and funding support from Baxter Healthcare for his research.

  • Debra Hickman: Preclinical Consultant

 Dr. Debra Hickman is the director of the Laboratory Animal Resource Center at the Indiana University Purdue University at Indianapolis. She has significant expertise in many neurodegenerative disease animal models using assessment of behavior matrices, learning and emotional coping efficacies. As the director and investigator, she has been active throughout her career in multiple clinic-pathological and drug evaluation studies.

  • Thyagarajan Venkatesan: Chief Financial Officer

Thyagarajan Venkatesan (Raj) is a highly accomplished financial executive with exceptional leadership skills and an extensive background experience in cash management, forecasting and budgeting, cost control methods and profitability analysis. With over 30 years of experience in established manufacturing and technology start-up companies, Raj will assist Provaidya LLC in all financial and tax operations.